Diaceutics plc
DXRX:LN
Latest Coverage
Overview
Company Profile
Diaceutics is a data analytics and implementation services company which services the global pharmaceutical industry. It has established a suite of data-driven products and implementation services powered by the data held in its proprietary database. Its products and services are focused on optimising its clients’ strategies for the development and launch of precision medicines and specifically, the diagnostic testing required to guide selection of such medicines. The Group currently provides services to 20 of the 30 largest global pharmaceutical companies.
Classification
Financials
News & Media
Latest Coverage
Corporate
Board of Directors
Peter Keeling
Chief Executive Officer
Peter has over 30 years’ experience as a leader, entrepreneur and strategist in the pharmaceutical industry. He has led international companies and teams with a focus on novel business models and product launches, including therapies, diagnostics and FMCG products. Peter started his career as Distribution Manager at American Monitor Corporation where he oversaw the distribution of reagents and equipment globally. He subsequently spent 11 years leading projects in both operational and strategic roles at the pharmaceutical division of the Wellcome Foundation, including Sales Manager for the pharmaceutical business in North and West Africa (4 years), Commercial Director for a joint venture with Wellcome Indonesia (3.5 years) and Brand Director at a global product level for Wellcome’s antiviral franchise (3.5 years). Wellcome was merged into Glaxo in 2004. Subsequently, he was Founder and Chief Executive Officer of Diagnology Inc, a US/Irish based diagnostics company which specialised in development and commercialisation of tests for sexually transmitted diseases. Peter has led Diaceutics from its inception in 2005 to become a leader in innovative solutions which currently services 20 of the world’s largest pharmaceutical companies. Peter holds a degree in business administration from Queens University Belfast, a Masters degree in European Marketing from Buckingham University Business School and spent an academic year as a Visiting Fellow at MIT’s Sloan business school in 1994 where he led a multi-corporation US think tank designed to look at disruptive healthcare models for the pharma industry. Peter has published several peer reviewed papers on precision medicine and is a respected speaker at precision medicine events around the world.
Philip White FCA
Chief Financial Officer
Philip has over 15 years’ management and financial experience, and has been Chief Financial Officer of Diaceutics since 2011. He is a fellow member of the Institute of Chartered Accountants in Ireland and of the Institute of Directors. Philip gained a degree in Law and Accountancy from Queens University Belfast, and has completed the SEP program at the London Business School. Prior to joining Diaceutics, Philip was involved in negotiation, execution and integration of corporate acquisitions through his role as director of Philip White Tyres Ltd. a family business. Philip has responsibility for all financial and risk management operations and works with the executive management team to develop and implement strategies across the organisation.
Charles Hindson
Non-Executive Director
Charles joins the board as a non-executive director, and chair of the audit and remuneration committees. He brings 16 years’ experience of FTSE listed company board membership, having served in executive director roles with Filtronic plc, firstly as Group Finance Director and subsequently Chief Executive, and then with e2v technologies plc, as Group Finance Director. He is experienced in supporting business leaders develop technology businesses internationally, through organic growth and successful acquisitions, and this has been reflected in creating meaningful shareholder value with these listed companies. His early career was with 3i and PwC, and then in HQ and international divisional finance roles with British Gas plc and British Telecom plc before becoming Finance Director with Eutelsat SA, based in Paris, France. He now also serves as a trustee of Trinity College London, the international exam board for performing arts and English language qualifications, and is a member of its audit committee.
Michael Wort
Non-Executive Director
Having trained as a microbiologist, Michael brings over 40 years’ experience working with life science companies across the healthcare sector. Initially working with three of the top ten global pharmaceutical companies in a variety of sales, marketing and research positions, he was appointed Investor Relations Manager of Wellcome Plc and was actively involved in the global communications programme for the major £2.3 billion secondary offering of Wellcome Plc shares by the Wellcome Trust, which enabled him to develop working relationships with key figures in the life sciences industry. After leaving Wellcome, Michael was a founding partner in the UK’s first specialist communications agency, for the emerging biotechnology industry. Apart from a diversion caused by his involvement as the CEO during the privatisation of the Bulgarian pharmaceutical industry his career has been devoted to working with start-up and growing SMEs to maximise their potential for growth.